search
Back to results

Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease (SCLERESPIR)

Primary Purpose

Systemic Sclerosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Rehabilitation
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Systemic Sclerosis focused on measuring Systemic Sclerosis, Lung disease, Rehabilitation, Respiratory deficiencies, Feasibility study

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Systemic sclerosis according to ACR/EULAR 2013 criteria
  • Disease duration < 7 years
  • Lung involvement, with FCV > 70% on PFT

Exclusion Criteria:

  • Inability to understand French
  • Pregnancy or breastfeeding
  • Arterial pulmonary hypertension > 35 mmHg and unexplained dyspnoea or arterial pulmonary hypertension > 40 mmHg
  • Major musculoskeletal impairment incompatible with physical activity
  • other pulmonary disease decreasing FCV
  • Pathological EKG
  • Oxygen saturation at rest or during physical activity < 90%
  • FCV < 70%

Sites / Locations

  • Service de rééducation fonctionnelle, réadaptation de l'appareil locomoteur et Pathologies du Rachis - Cochin Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Home based exercises

Arm Description

1 supervised session in the outpatient rehabilitation department with respiratory, aerobic and muscles strengthening exercises, followed by 3 months of self-manage personalized home exercises program. Cardiac frequency and adherence to exercise will be monitored using an activity tracker (Garmin© watch).

Outcomes

Primary Outcome Measures

Number of lost to follow up patients
Adherence to treatment
Number of uncompleted questionnaires
Adherence to treatment
Amount of aerobic work recorded using a connected watch
Adherence to treatment / Amount of aerobic work recorded using a connected watch with heart rate monitor
Amount of exercises self-reported in a logbook
Adherence to treatment
Exercise Adherence Rating Scale (EARS) questionnaire
Adherence to treatment / Amount of exercises
Self-reported adherence
Adherence to treatment
Exercise Adherence Rating Scale (EARS) questionnaire
Adherence to treatment
Treatment burden assess by the Exercise Therapy Burden Questionnaire (ETBQ)
Adherence to treatment / Burden of program
Check-list to report side effects
Adherence to treatment

Secondary Outcome Measures

Lung volume
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Lung volume
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Diffusing capacity
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Diffusing capacity
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Maximal oxygen consumption during a 6 minute walking test
Aerobic capacity / Variation between base line and 3 months
Maximal oxygen consumption during a 6 minute walking test
Aerobic capacity / Variation between base line and 3 months
Saint Georges hospital questionnaire
Activity limitations specific to respiratory function / Variation between base line and 3 months
Saint Georges hospital questionnaire
Activity limitations specific to respiratory function / Variation between base line and 3 months
Health Assessment Questionnaire (HAQ)
Overall activity limitations / Variation between base line and 3 months
Health Assessment Questionnaire (HAQ)
Overall activity limitations / Variation between base line and 3 months
12-Items short form survey questionnaire (SF-12)
Quality of life / Variation between base line and 3 months
12-Items short form survey questionnaire (SF-12)
Quality of life / Variation between base line and 3 months

Full Information

First Posted
July 7, 2022
Last Updated
September 6, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT05533034
Brief Title
Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease
Acronym
SCLERESPIR
Official Title
Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease: Pilot Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Systematic sclerosis (SSc) is a potentially severe disease characterized by various visceral involvements including lung. The investigators hypothesize that a respiratory rehabilitation program specifically designed for people with systematic sclerosis with early lung disease could help to decrease respiratory deficiencies, improve aerobic capacity and prevent activity limitations and participation restrictions. Before testing the effectiveness of such a program, a pilot study is needed to assess its feasibility and optimize its content. Participants will have 1 supervised session in the outpatient rehabilitation department. Each patient will then perform the home personalized exercises program for 3 months. The feasibility of the program will be assessed at 3 months using patients' adherence to the program (assessed by the number of lost to follow-up, the number of questionnaires not completed, the amount of aerobic activity and the amount of home personalized exercises, treatment burden, adverse effects and quality of life.
Detailed Description
SSc is responsible for a reduced life expectancy. The prognosis depends on the presence of severe visceral damage and more particularly on the presence of interstitial lung damage, pulmonary arterial hypertension or specific cardiac damage which represent the 3 main causes of mortality in SSc. The importance of rehabilitation in SSc has been confirmed by the latest INSERM Collective Expertise 2019). The objectives of functional rehabilitation in SSc are to prevent and/or reduce the specific (cutaneous, oral, cardiorespiratory, musculoskeletal) and non-specific (exercise deconditioning, fatigue, anxiety and depression) impairments frequently characterizing the evolution of the disease. Based on the latest practice recommendations for the diagnosis and treatment of idiopathic pulmonary fibrosis, people with a confirmed diagnosis of idiopathic pulmonary fibrosis and significant exercise and activity limitations should follow a respiratory rehabilitation program. The value of a specific respiratory rehabilitation program for people with SSc is then a matter of interest. A pilot study is needed to assess the feasibility and optimize the content of a rehabilitation program. The investigators aimed to study the feasibility of a personalized home-based respiratory rehabilitation program in people with SSc with early lung disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis
Keywords
Systemic Sclerosis, Lung disease, Rehabilitation, Respiratory deficiencies, Feasibility study

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Home based exercises
Arm Type
Experimental
Arm Description
1 supervised session in the outpatient rehabilitation department with respiratory, aerobic and muscles strengthening exercises, followed by 3 months of self-manage personalized home exercises program. Cardiac frequency and adherence to exercise will be monitored using an activity tracker (Garmin© watch).
Intervention Type
Other
Intervention Name(s)
Rehabilitation
Other Intervention Name(s)
Personalized home exercises program
Intervention Description
1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs. 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence.
Primary Outcome Measure Information:
Title
Number of lost to follow up patients
Description
Adherence to treatment
Time Frame
3 months
Title
Number of uncompleted questionnaires
Description
Adherence to treatment
Time Frame
3 months
Title
Amount of aerobic work recorded using a connected watch
Description
Adherence to treatment / Amount of aerobic work recorded using a connected watch with heart rate monitor
Time Frame
3 months
Title
Amount of exercises self-reported in a logbook
Description
Adherence to treatment
Time Frame
3 months
Title
Exercise Adherence Rating Scale (EARS) questionnaire
Description
Adherence to treatment / Amount of exercises
Time Frame
3 months
Title
Self-reported adherence
Description
Adherence to treatment
Time Frame
3 months
Title
Exercise Adherence Rating Scale (EARS) questionnaire
Description
Adherence to treatment
Time Frame
3 months
Title
Treatment burden assess by the Exercise Therapy Burden Questionnaire (ETBQ)
Description
Adherence to treatment / Burden of program
Time Frame
3 months
Title
Check-list to report side effects
Description
Adherence to treatment
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Lung volume
Description
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
Lung volume
Description
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Time Frame
3 months
Title
Diffusing capacity
Description
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
Diffusing capacity
Description
Pulmonary Function Testing (PFT) - Respiratory function / Variation between base line and 3 months
Time Frame
3 months
Title
Maximal oxygen consumption during a 6 minute walking test
Description
Aerobic capacity / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
Maximal oxygen consumption during a 6 minute walking test
Description
Aerobic capacity / Variation between base line and 3 months
Time Frame
3 months
Title
Saint Georges hospital questionnaire
Description
Activity limitations specific to respiratory function / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
Saint Georges hospital questionnaire
Description
Activity limitations specific to respiratory function / Variation between base line and 3 months
Time Frame
3 months
Title
Health Assessment Questionnaire (HAQ)
Description
Overall activity limitations / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
Health Assessment Questionnaire (HAQ)
Description
Overall activity limitations / Variation between base line and 3 months
Time Frame
3 months
Title
12-Items short form survey questionnaire (SF-12)
Description
Quality of life / Variation between base line and 3 months
Time Frame
Day of inclusion
Title
12-Items short form survey questionnaire (SF-12)
Description
Quality of life / Variation between base line and 3 months
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Systemic sclerosis according to ACR/EULAR 2013 criteria Disease duration < 7 years Lung involvement, with FCV > 70% on PFT Exclusion Criteria: Inability to understand French Pregnancy or breastfeeding Arterial pulmonary hypertension > 35 mmHg and unexplained dyspnoea or arterial pulmonary hypertension > 40 mmHg Major musculoskeletal impairment incompatible with physical activity other pulmonary disease decreasing FCV Pathological EKG Oxygen saturation at rest or during physical activity < 90% FCV < 70%
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra ROREN, PhD
Phone
00 33 1 58 41 13 71
Email
alexandra.roren@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Marie BENHAMMANI-GODARD
Phone
0033 1 58411190
Email
marie.godard@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Camille DASTE, MD
Organizational Affiliation
Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christelle NGUYEN, MD, PhD
Organizational Affiliation
Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
Official's Role
Study Director
Facility Information:
Facility Name
Service de rééducation fonctionnelle, réadaptation de l'appareil locomoteur et Pathologies du Rachis - Cochin Hospital
City
Paris
State/Province
Ile De France
ZIP/Postal Code
75014
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra ROREN
Phone
0033158411371
Email
alexandra.roren@aphp.fr
First Name & Middle Initial & Last Name & Degree
Camille DASTE, MD
First Name & Middle Initial & Last Name & Degree
Benjamin CHAIGNE, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease

We'll reach out to this number within 24 hrs